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Abstract
Background: Mycoplasma hyopneumoniae is the primary cause of enzootic pneumonia in pigs. Although
vaccination is an important control tool, the results observed under field conditions are variable. This may be due
to antigenic differences between the strains circulating in pig herds and the vaccine strain. This study compared
the protective efficacy of four bacterins against challenge infection with a highly virulent field strain of M.
hyopneumoniae.
Seventy eight, one-week old piglets were randomly assigned to five treatment groups (A, B, C, D, E), 14 piglets
each, and a negative control group (F) consisting of 8 piglets. All pigs were injected at 1 (D7) and 4 weeks of age
(D28), with 2 ml of either a placebo or a bacterin based on selected M. hyopneumoniae strains, namely A (F7.2C), B
(F20.1L), C (B2V1W20 1A-F), D (J strain), E (placebo; positive control), F (placebo; negative control). At D56, all pigs
except those of group F were challenged intratracheally with 7 ml culture medium containing 10
7 CCU/ml of M.
hyopneumoniae strain F7.2C. All pigs were euthanized and necropsied at D84. The severity of coughing and
pneumonia lesions were the main parameters. Immunofluorescence (IF) testing, nested PCR testing of
bronchoalveolar lavage (BAL) fluid and serology for M. hyopneumoniae were also performed.
Results: The different bacterins only slightly improved clinical symptoms (average 0.38 in vaccinated groups vs.
0.45 in group E) and histopathological lung lesions (average 3.20 in vaccinated groups vs. 3.45 in group E), but did
not improve macroscopic lung lesions (score 4.30 vs. 4.03 in group E). None of the vaccines was significantly and/
or consistently better or worse than the other ones. All bacterins evoked a serological response in the vaccinated
animals. All pigs, except those from group F, were positive with nPCR in BAL fluid at D84.
Conclusion: The bacterins did not induce a clear overall protection against challenge infection, and there were no
significant differences in protective efficacy between bacterins containing homologous and heterologous M.
hyopneumoniae strains. Further research is necessary to better characterize the antigens involved in protection and
to elucidate the protective immunity responses following M. hyopneumoniae vaccination and/or infection.
Background
Mycoplasma hyopneumoniae is the primary cause of
enzootic pneumonia in pigs, a disease causing major
economic losses to the pig industry worldwide due to
reduced performance and increased medication [1,2].
Control of enzootic pneumonia can be accomplished by
optimizing herd management practices and housing
conditions, and by using antimicrobial medication and/
or vaccination [2-4].
Vaccination with the commercially available vaccines
is frequently practiced worldwide. Most vaccines are
adjuvanted bacterins, and they generally provide good
results in terms of improving clinical symptoms and
lung lesions, and in decreasing performance losses and
antimicrobial medication due to M. hyopneumoniae
infections. However, the effects of vaccination may vary
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ditions, it has been shown that the effects of vaccination
differ depending on the challenge strain used to inocu-
late the animals [5]. The variable results observed under
field conditions may be due, among other factors, to
antigenic differences between the strains circulating in
pig herds and the vaccine strain. Previous studies have
demonstrated that M. hyopneumoniae strains circulating
in pig herds display considerable variation at genomic
[6] and protein level [7], and also in terms of virulence,
major differences between strains have been demon-
strated [8,9]. The current commercial vaccines used to
control enzootic pneumonia are mostly based on the J-
strain, which was originally isolated from a pig herd in
the UK (Goodwin and Whittlestone, 1963). It can there-
fore be questioned whether this strain has similar char-
acteristics as the M. hyopneumoniae strains circulating
in pig herds in other parts of the world [6,10].
The aim of this study was to compare the protective
efficacy of four bacterins against challenge infection
with a highly virulent field strain of M. hyopneumoniae.
One of the bacterins was based on the challenge strain,
two were based on other M. hyopneumoniae field strains
and one contained the J strain.
Methods
Animals and experimental design
S e v e n t ye i g h tc r o s s - b r e dp i g sf r o mah e r df r e eo fM.
hyopneumoniae were included in the study. The herd
was free from M. hyopneumoniae for more than 10
years based on regular monitoring of clinical symptoms,
pneumonia lesions at slaughter, and serological testing
for presence of antibodies against M. hyopneumoniae.
The piglets were weaned at one week of age, and trans-
ported to the experimental facilities. They were ran-
domly allocated to five different treatment groups (A, B,
C, D, E) of 14 piglets each, and a negative control group
(F) of 8 piglets. Every group was housed in a different
room and each room had an own ventilation system to
avoid transmission of infection from one group to
another.
Pigs were vaccinated twice intramuscularly with 2 ml
of either a placebo consisting of phosphate buffered sal-
ine solution (groups E and F) or a bacterin (groups A-
D). The first time, they were vaccinated one day after
transport to the experimental facilities (D7) and again
three weeks later (D28). Vaccines A, B and C were
based on field strains: A on F7.2C, B on F20.1L, and C
on B2V1W20 1A-F. Previous studies revealed that these
strains are genetically and antigenically different [7,11].
Vaccine D was based on the J strain (Mypravac suis
®,
laboratorios HIPRA).
Four weeks after the second vaccination (D56), all pigs
of groups A-E were challenged intratracheally with 7 ml
of culture medium containing 10
7 CCU/ml of M. hyop-
neumoniae strain F7.2C. Therefore, the pigs were anaes-
thetized with 0.22 ml/kg of a mixture of Xyl-M
® 2%
(Intervet) and Zoletil 100
® (Virbac). The negative con-
trol group F was inoculated intratracheally with 7 ml of
M. hyopneumoniae culture medium. All pigs were
euthanized and necropsied 4 weeks after challenge infec-
tion (D84). Therefore, deep anaesthesia was applied by
administrating intramuscularly 0.3 ml/kg of a mixture of
XylM
® 2% and Zoletil 100
®, followed by exsanguination.
The experimental design and the different groups are
presented in Table 1.
The study was conducted after approval of the ethical
committee for conducting animal experiments within
CEYC (approval number EID-2009-031).
Preparation of the bacterins
The selected M. hyopneumoniae strains for producing
bacterins A, B and C, together with the J strain, were
cultured during three weeks in modified Friis’ medium
[12] at 37°C in an atmosphere containing 5% CO2. The
Mycoplasmas were inactivated with binary ethylamine to
obtain a whole-cell bacterin in an aqueous adjuvant sus-
pension. All bacterins were adjusted to the same M.
Table 1 Different groups and experimental design.
Group Number of pigs Strain used in bacterin Challenge infection at D56 Necropsy at D84
A 14 F7.2C + +
B 14 F20.1L + +
C 14 B2V1W20 1A-F + +
D 14 J strain + +
E 14 placebo
a ++
F 8 placebo
a -
b +
Legend: This table shows efficacy of different M. hyopneumoniae bacterins against challenge infection with a highly virulent M. hyopneumoniae strain. Pigs in
each group were injected intramuscularly at D7 and D28 with the respective bacterins or a placebo solution. Euthanasia of all pigs was performed on D84.
a Phosphate buffered saline solution was used as placebo for the vaccination
b M. hyopneumoniae culture medium was used as placebo for the challenge infection
c Pigs were intratracheally inoculated with 7 ml of 10
7 CCU/ml M. hyopneumoniae strain F7.2C. at D56
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CCU/ml, before inactivation.
Parameters of comparison and sampling of pigs
Clinical parameters
After intratracheal inoculation and until the end of the
study, piglets were observed daily for a minimum of 15
minutes. The severity of coughing was assessed using a
respiratory disease score (RDS) as described by Halbur
et al. [13]. Body condition, appetite, presence of dyspnea
and tachypnea were also recorded. The RDS could
range from 0 to 6: 0 (no coughing), 1 (mild coughing
after an encouraged move), 2 (mild coughing in rest), 3
(moderate coughing after encouraged move), 4 (moder-
ate coughing in rest), 5 (severe coughing after encour-
aged move), 6 (severe coughing in rest). The daily RDS
values were summed and averaged on D84.
Macroscopic lung lesions, histopathology and
immunofluorescence (IF) testing for M. hyopneumoniae
After necropsy, the lungs were removed to score the
macroscopic pneumonia lesions according to Hannan et
al. [14], with values ranging from 0 (no lesions) to 35
(entire lung affected). Samples from the right apical, car-
dial and diaphragmatic lung lobe of each pig were col-
lected for histopathological examination and IF testing.
If lung lesions were present, tissue samples for IF testing
were collected from the edge of a lesion.
For histopathological examination, the lung tissue
samples were fixed in 10% neutral formalin, processed
and embedded in paraffin. After hematoxylin and eosin
staining, samples were scored using light microscopy.
Scores could range from 0 to 5, according to the degree
of peribronchiolar and perivascular lymphohistiocytic
infiltration, as well as cuffing formation [15,16]. Scores 1
(limited cellular infiltrates- macrophages and lympho-
cyte- around bronchioles; with airways and alveolar
spaces free of cellular exudates) and 2 (moderate infil-
trates with mild diffuse cellular exudates into airways)
were classified as lesions not related to Mycoplasma
i n f e c t i o n s .S c o r e s3 ,4 ,5w e r ec o n s i d e r e dt ob ea s s o -
ciated with Mycoplasma infection (mild, moderate or
severe- broncho-interstitial (cuffing) pneumonia, sur-
rounding bronchioles but extending to the interstitium,
with lymphofollicular infiltration and mixed inflamma-
tory cell exudates). The average histopathological lung
score per group was calculated.
A direct IF assay [17] was performed to assess the
load of M. hyopneumoniae organisms in a semi-quanti-
tative way. The scores could range ranged from 0 to 3:
0 (no IF), 1 (limited IF), 2 (moderate IF), and 3 (intense
IF) [8].
Nasal swabs, bronchoalveolar lavage fluid, and nPCR
Nasal swabs were collected from all animals at D7, D28,
D56, D70 and just before euthanasia on D84. At
necropsy on D84, 20 ml of PBS were slowly infused in
the left lung and aspirated back into the syringe. The
recovered bronchoalveolar lavage (BAL) fluid was ali-
quoted, immediately cooled at 4°C, and subsequently
stored at -70°C until analysis.
DNA was extracted from the nasal swabs and BAL
fluid with the QIAGEN protocol for purification of
total DNA from animal blood and tissues (QIAGEN,
DNeasy Blood & Tissue Kit, Belgium). For detection of
M. hyopneumoniae DNA, a nPCR-test based on a
modified protocol described by Stärk et al. [18] was
performed [16].
Serology
Blood samples were taken from all pigs at D7, D28, D56,
D70 and D84 and tested for the presence of antibodies
against M. hyopneumoniae using the DAKO
® Mhyo
ELISA (Oxoid Limited, Hampshire, UK). Sera with inhi-
bition percentage (IP) > 50% were considered positive,
IP values < 50% were considered negative. Intermediate
IP values were considered doubtful and classified as
negative for the data analysis.
DWG and FCR
Pigs were individually weighed on D7, D28, D56, D70
and D84. The daily weight gain (DWG) and feed con-
version ratio (FCR) were calculated for all groups. The
DWG (g/day) for different periods during the study was
estimated from the difference between the starting and
final weight at a period, divided by the number of days
lived by the pigs during that period. The FCR was calcu-
lated as the amount of feed consumed divided by the
mean increase in live weight during each period.
Bacteriology
A sample of BAL fluid per pig in each group was inocu-
lated on Columbia agar supplemented with 5% sheep
blood (Oxoid, Hampshire, UK) with a Staphylococcus
pseudintermedius streak for support of Actinobacillus
and Haemophilus sp. growth, and on Columbia CNA
agar with 5% sheep blood (Oxoid, Hampshire, UK). As
described by Quinn et al. [19], plates were incubated in
a 5% CO2-enriched environment at 37°C for 48 h for
identification of respiratory bacteria in the lungs.
Statistical analysis
The RDS scores, macroscopic, histopathological lung
lesions, IF scores, serology (IP values) and DWG in the
different groups were statistically analyzed using one-
way analysis of variance (ANOVA). For each parameter,
pair-wise comparisons between groups were obtained
using Bonferroni’st e s t .T h ep r o p o r t i o n of serologically
positive pigs, and pigs positive by nested PCR on nasal
swabs and BALF at different time points (D7, D28, D56,
D70 and D84) were analyzed using logistic regression.
G r o u pFw a se x c l u d e df r o mt h estatistical analysis as
this group only served as a sentinel group.
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0.05 (two-sided test). The statistical package SPSS 17.0
for Windows (SPSS 17.0, SPSS Inc., IL, USA) was used
for the analysis.
Results
Clinical parameters
Throughout the total duration of the trial, coughing was
absent in group F. The onset of coughing occurred first
in groups C and E at 7-8 DPI, followed by group B, D
and A at 11, 13 and 14 DPI, respectively. The RDS
recorded for groups A, B, C, D, E and F were 0.29, 0.50,
0.53, 0.18, 0.61 and 0, respectively (Table 2). No signifi-
cant differences were observed between groups A, B, C
and E (P > 0.05). The RDS was significantly lower in
group D than in group E (P < 0.05).
Macroscopic, histopathological lung lesions and IF testing
for M. hyopneumoniae
The macroscopic lung lesion scores in groups A, B, C,
D, E and F were 6.86, 2.59, 3.33, 4.59, 4.06 and 0.23,
respectively. Only two pigs had very mild lung lesions in
group F. Group A had significantly higher scores than
group B and C (P < 0.05). There were no significant dif-
ferences between groups B, C, D and E (Table 1).
The scores for the histopathological lung lesions in
groups A, B, C, D, and E were 3.49, 3.48, 2.89, 2.93 and
3.45, respectively (P > 0.05) (Table 1). The pigs in group F
did not show Mycoplasma-like histopathological lesions.
The average score (1.29) in group F was significantly lower
than the scores of the other groups (P < 0.05).
All pigs, except for those in group F, were positive for
IF staining. The highest IF score was recorded in group
E (2.23), the lowest in group B (0.91) (P < 0.01). The
scores in groups A, C and D were 1.63, 1.27 and 1.77,
respectively (P > 0.05). One pig from group F had a
positive IF testing in one of the 3 sampled lobes.
nPCR testing on nasal swabs and BAL fluid
Presence of M. hyopneumoniae was confirmed in all
infected groups. The results of the nPCR on nasal swabs
at different points and the nPCR testing on BAL fluid at
D84 are presented in Table 3. All animals in group F
tested negative at all time-points. The majority of the
animals in the infected groups (A-E) tested positive in
nasal swabs at D70 and D84. All of them were positive
in the BAL fluid at D84.
Serology
The percentage of seropositive pigs in each group and
the average IP values are presented in Table 4. Piglets in
group F remained negative throughout the entire study.
All pigs from groups A-E tested serologically negative at
D7. The first seropositive pigs were identified at D28 i.e.
3 weeks after the first vaccination, in all vaccinated
groups except for group A. The pigs of group E
remained serologically negative until 2 weeks after chal-
lenge infection (D70). At that time (D70), 60% of the
pigs were serologically positive in group E, whereas all
pigs were serologically positive in the vaccinated groups
(A-D). At D84, all pigs from groups A-E were serologi-
cally positive.
Bacteriology
No relevant bacterial growth was observed at 2, 4, nor 7
days after plating the BALF samples on Columbia blood
agar and CNA plates.
Table 2 Results (mean ± SD) of the different parameters.
Parameter Treatment group
ABC DE F
RDS 0.29 ± 0.09
a,b,c 0.50 ± 0.21
a,b 0.53 ± 0.25
a,b 0.18 ± 0.14
,a,c 0.61 ± 0.32
b 0.00 ± 0.00
c
Macroscopic lung lesions 6.86 ± 4.54
a 2.59 ± 1.39
b,c 3.33 ± 0.97
b,c 4.59 ± 2.82
a,b,c 4.06 ± 2.45
a,b 0.23 ± 0.35
c
Histopathological lung lesions 3.49 ± 0.67
a 3.48 ± 0.65
a 2.89 ± 0.74
a 2.93 ± 0.76
a 3.45 ± 0.73
a 1.29 ± 0.30
a
IF 1.63 ± 0.97
a,b 0.91 ± 0.86
a,c 1.27 ± 0.21
a,b,c 1.77 ± 0.70
a,b 2.23 ± 1.05
b 0.14 ± 0.38
c
Respiratory disease score (RDS), macroscopic and histopathological lung lesions, and immunofluorescence (IF) scores for M. hyopneumoniae in the lung tissue in
the different groups (Groups A-E: n = 14 pigs per group; group F: n = 8 pigs)
Group A (F7.2C), B (F20.1L), C (B2V1W20 1A-F), D (J strain), E (positive control; non-vaccinated, challenge infected), F (negative control; non-vaccinated, non-
challenged).
Within a row, different superscript letters correspond to significant differences between the groups (P < 0.05)
Table 3 Number (%) of positive pigs by nested PCR.
Age of pigs Treatment group
AB C D E F
D7 0/14 0/14 0/14 0/14 0/14 0/14
D28 0/11 0/12 0/9 0/11 0/11 0/7
D56 0/11 0/12 0/8 0/11 0/11 0/7
D70 6/10
a,b 6/11
a,b 7/7
a 8/10
a 7/10
a 0/7
D84 7/10 7/11 3/5 5/10 7/10 0/7
D84 (BALF) 10/10 10/10 5/5 10/10 10/10 0/7
Legend: nested PCR was carried on nasal swabs (D7, D28, D56, D70, D84) and
bronchoalveolar lavage fluid (BALF) (D84) throughout the trial (Groups A-E: n
= 14 pigs per group; group F: n = 8 pigs)
Group A (F7.2C), B (F20.1L), C (B2V1W20 1A-F), D (J strain), E (positive control;
non-vaccinated, challenge infected), F (negative control; non-vaccinated, non-
challenged).
Within a row, different superscript letters correspond to significant differences
between the groups (P < 0.05). Group F was not included in the statistical analysis.
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The results of DWG and FCR are presented in Table 5.
Significant differences between groups for DWG were only
observed during the specific periods of the study (D28-
D56, D56-D70, D70-D84), but there were no significant
differences for the entire study period (D28-D84). The
overall DWG was highest in groups A, D and F. These
groups together with group B also had the lowest FCR.
The number of pigs that died in the different groups
w e r e4 ,3 ,9 ,4 ,4a n d1i ng r o u p sA ,B ,C ,D ,Ea n dF ,
respectively. The majority of them died during the pre-
challenge phase due to E. coli diarrhea. One animal died
during anesthesia, and in two other animals (group C), a
non-serotypable Streptococcus suis strain was isolated
from the lung and from the lung and liver, respectively.
Clinically diseased pigs were medicated per os (1 ml/pig-
let) with a combination of gentamicin, sulfadimidin, tri-
methoprim and dexamethasone (Coliprajet
®,H i p r a )f o r
3 consecutive days.
Discussion
In the present study, all bacterins evoked a serological
response in the vaccinated animals. However, after chal-
lenge with a highly virulent M. hyopneumoniae strain, a
clear protection against macroscopic lung lesions was
not demonstrated in these animals. This confirms a lack
of correlation between serum antibodies and protection
[20-22]. Studies aiming to elucidate immune mechan-
isms playing a role in protection against infection with
this very fastidious micro-organism are urgently needed.
It is remarkable that vaccination with a bacterin based
on the homologous M. hyopneumoniae strain did not
result in an increased protection in comparison with
bacterins containing other strains, including the J-strain
which has been shown to be antigenically quite different
from the challenge strain [7,11]. In a previous study, it
was demonstrated that the effect of vaccination with a
whole cell bacterin on the course of an experimental M.
hyopneumoniae infection may vary, depending on the
Table 4 Percentage of seropositive pigs and inhibition percentage (IP) in each group.
Age of pigs Treatment group
ABCDE F
D7 0 0 0 0 0 0
D28 0
A,C (35.5)
a 17
A (36.2)
a 89
B (54.9)
b 9
A (32.7)
a 0
C (8.34)
c 0
D56 100
A (76.4)
a 100
A (75.5)
a 100
A (89.3)
b 100
A (73.4)
a 0
B (14.1)
c 0
D70 100
A (92.6)
a 100
A (92.7)
a 100
A (93.5)
a 100
A (93.6)
a 60
B (63.6)
b 0
D84 100 (96.4)
a 100 (96.3)
a 100 (96.7)
a 100 (96.4)
a 100 (84.9)
b 0
Legend: Serology was performed using DAKO
® M.hyo ELISA (Oxoid Limited, Hampshire, UK) for Mycoplasma hyopneumoniae in each group (Groups A-E: n = 14
pigs per group; group F: n = 8 pigs)
Group A (F7.2C), B (F20.1L), C (B2V1W20 1A-F), D (J strain), E (positive control; non-vaccinated, challenge infected), F (negative control; non-vaccinated, non-
challenged).
Sera with IP value > 50% was considered positive, IP values < 50% were considered negative. Intermediate IP values were considered doubtful and classified as
negative.
Within a row, different superscript letters correspond to significant differences between the groups (P < 0.05): capital letters for the proportion of seropositive
pigs, lowercase letters for the IP values. Group F was not included in the statistical analysis.
Table 5 Daily weight gain (DWG) (g/day) (mean ± SD) and feed conversion rate (FCR) for each group (A-F).
Period Parameter Treatment group
AB C DEF
D7-28 DWG 154.5 (72.2) 155.9 (64.4) 146.9 (64.6) 151.3 (49.6) 158.7 (42.0) 180.5 (49.0)
D28-56 DWG 415.5 (92.2) 353.9 (110.9) 315.6
a (92.5) 359.2 (76.4) 338.9 (87.8) 469.1
b (118.1)
FCR 1.38 1.18 1.30 1.42 1.50 1.31
D56-70 DWG 449.8
a,b (252.5) 425.5
a,b (213.3) 293.8
a (157.9) 632.9
b (143.0) 506.4
a,b (221.7) 700.7
b (222.0)
FCR 2.00 2.07 2.37 1.50 1.90 1.56
D70-84 DWG 697.1 (61.4) 679.9 (113.5) 505.7 (42.0) 552.8
a,b(144.0) 653.2 (97.2) 654.9
b (169.4)
FCR 1.77 1.72 2.13 1.92 1.87 1.78
D28-84 DWG 491.7 (84.7) 452.7 (146.4) 413.3 (63.2) 486.7 (76.1) 460.3 (101.6) 486.7 (106.9)
FCR 1.74 1.72 2.04 1.61 1.80 1.52
Legend: Groups A-E: n = 14 pigs per group; group F: n = 8 pigs.
Group A (F7.2C), B (F20.1L), C (B2V1W20 1A-F), D (J strain), E (positive control; non-vaccinated, challenge infected), F (negative control; non-vaccinated, non-
challenged).
No FCR was measured during D7-28
Within a row, different superscripts correspond to significant differences between groups (P < 0.05). As FCR was measured at group level, no statistical analysis
was done to compare the groups.
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required to elucidate the importance of the M. hyopneu-
moniae strain included in the vaccine for induction of
protection. Such studies may include vaccines with dif-
ferent amounts of antigen and different adjuvants.
The challenge infection was successful because in all
infected pigs, lung lesions were induced and M. hyop-
neumoniae was demonstrated by nPCR testing in BAL
fluid at the end of the study. The values for RDS and
lung lesions in the positive control group E (non-vacci-
nated, infected) were similar to those found in previous
experimental studies using the same challenge strain
[4,5,16]. Based on nPCR testing, serology and histo-
pathology, the negative control group F remained nega-
tive for M. hyopneumoniae throughout the study. This
confirms that the pigs used in this study were free of M.
hyopneumoniae. It is not clear which pathogen may
have caused the very mild pneumonia lesions in two
pigs of group F, and neither what may be the reason for
the positive IF testing found in one of these pigs (only
one of the three sampled lung lobes).
Vaccination with commercial M. hyopneumoniae bac-
terins generally provides significant improvement of
clinical symptoms and lung lesions [1,2]. In the present
study, clinical symptoms (average 0.38 in vaccinated
groups versus 0.45 in group E) and histopathological
lesions (average 3.20 in vaccinated groups versus 3.45 in
group E) were lower in the vaccinated groups, but the
difference was only moderate, and smaller than in pre-
vious experimental infection studies [5,16]. In addition,
the macroscopic lung lesions in the vaccinated groups
(4.34) were on average similar to those in the positive
control group (4.03). The reasons for this are not clear.
The number of M. hyopneumoniae organisms was kept
similar in the different bacterins to avoid that concen-
tration of M. hyopneumoniae cells in the different bac-
terins would have biased the results. It is possible that
the concentration in the bacterins of the present study
(7.7 log10 CCU/ml, before inactivation) was lower than
in commercial bacterins, and that this can (partially)
explain the poor or moderate efficacy. The antigen con-
centration in commercial bacterins is expressed in dif-
ferent units and therefore not directly comparable with
the concentration of the present bacterins.
T h eb a c t e r i n si nt h ep r e s e n ts t u d yw e r en o ta b l et o
prevent colonization nor to eliminate M. hyopeumoniae
from the lung tissue, as the percentage of pigs with
positive nPCR in nasal swabs and BAL fluid were the
same for groups A-E. Previous studies had shown that
also commercial vaccines cannot prevent colonization
with M. hyopneumoniae and are not able to significantly
reduce the transmission of the organism. All bacterins
did induce serum antibodies rather quickly, as in all vac-
cinated groups except for group A, serum antibodies
were already detected at D28 i.e. 3 weeks after the first
vaccination. At the time of challenge (D56), all vacci-
nated pigs had detectable serum antibodies.
Performance parameters are generally included in
experimental studies with M. hyopneumoniae [5,8]
mainly because it is not that cumbersome to weigh a
small number of pigs and to measure feed consumption.
In general, no significant results are obtained because of
the high standard deviation for these parameters and
the rather small number of pigs included in experimen-
tal studies. This was also the case in the present study.
The rather high number of pigs that died during the
study, mainly due to E. coli infection before challenge,
may also have influenced the performance of the pigs.
Although performance parameters are very important
from a financial point of view, these parameters are bet-
ter investigated under practical circumstances rather
than under experimental conditions.
Conclusion
In conclusion, no significant differences in protective
efficacy were observed between three newly developed
bacterins based on M. hyopneumoniae field strains and
a bacterin based on the J-strain. Further research is
necessary to better characterize the antigens involved in
protection and to elucidate the protective immunity
responses following M. hyopneumoniae vaccination and/
or infection.
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